文献速递膀胱癌与上尿路尿路上皮癌

基于人工智能病理检测预测高危非肌层浸润性膀胱癌对膀胱内卡介苗治疗的反应:国际12中心队列的开发与验证

Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort.
PubMed 文献 · J Urol · 2024-10-09

研究利用人工智能从经尿道膀胱肿瘤电切术病理图像提取特征,开发并验证预测高危非肌层浸润性膀胱癌患者接受膀胱内卡介苗治疗后复发、进展、卡介苗无反应性疾病及膀胱切除术风险的检测方法,国际12中心944例数据支持其预测价值。

要点

  • 验证队列中高复发风险组高级别无复发生存劣于低复发风险组(HR 2.08,P<.0001)。
  • 高进展风险组无进展生存更差(HR 3.87,P<.001)且膀胱切除术风险更高(HR 3.35,P<.001)。
  • 携带卡介苗无反应疾病特征者发生卡介苗无反应疾病时间更短(HR 2.31,P<.0001)。

核心结论

  • 开发并验证了基于人工智能的组织学检测方法,可识别高危非肌层浸润性膀胱癌中复发、进展、卡介苗无反应性疾病及膀胱切除术风险较高的病例,可能有助于临床决策。

研究设计与样本

  • 国际12中心开发与验证队列研究,纳入接受卡介苗治疗的高危非肌层浸润性膀胱癌病例,获取卡介苗治疗前经尿道膀胱肿瘤电切术全切片图像及临床数据,通过分割与特征提取流程分析,并在独立的开发队列和验证队列中测试与临床结局相关的特征。

主要发现

  • 共纳入944例(开发队列303例,验证队列641例,中位随访36个月),高级别Ta占34.1%,高级别T1占54.8%,仅原位癌占11.1%,任何原位癌占31.4%。
  • 验证队列中高复发风险组高级别无复发生存劣于低复发风险组(HR 2.08,P<.0001)。
  • 高进展风险组无进展生存差于低进展风险组(HR 3.87,P<.001),且膀胱切除术风险高于低进展风险组(HR 3.35,P<.001)。
  • 携带卡介苗无反应疾病特征者发生卡介苗无反应疾病的时间短于无该特征者(HR 2.31,P<.0001)。
  • 人工智能检测提供的预测信息超出临床病理因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are few markers to identify those likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG). We developed and validated artificial intelligence (AI)-based histologic assays that extract interpretable features from transurethral resection of bladder tumor digitized pathology images to predict risk of recurrence, progression, development of BCG-unresponsive disease, and cystectomy. MATERIALS AND METHODS: Pre-BCG resection-derived whole-slide images and clinical data were obtained for high-risk nonmuscle-invasive bladder cancer cases treated with BCG from 12 centers and were analyzed through a segmentation and feature extraction pipeline. Features associated with clinical outcomes were defined and tested on independent development and validation cohorts. Cases were classified into high or low risk for recurrence, progression, BCG-unresponsive disease, and cystectomy. RESULTS: Nine hundred forty-four cases (development: 303, validation: 641, median follow-up: 36 months) representative of the intended use population were included (high-grade Ta: 34.1%, high-grade T1: 54.8%; carcinoma in situ only: 11.1%, any carcinoma in situ: 31.4%). In the validation cohort, "high recurrence risk" cases had inferior high-grade recurrence-free survival vs "low recurrence risk" cases (HR, 2.08, P < .0001). "High progression risk" patients had poorer progression-free survival (HR, 3.87, P < .001) and higher risk of cystectomy (HR, 3.35, P < .001) than "low progression risk" patients. Cases harboring the BCG-unresponsive disease signature had a shorter time to development of BCG-unresponsive disease than cases without the signature (HR, 2.31, P < .0001). AI assays provided predictive information beyond clinicopathologic factors. CONCLUSIONS: We developed and validated AI-based histologic assays that identify high-risk nonmuscle-invasive bladder cancer cases at higher risk of recurrence, progression, BCG-unresponsive disease, and cystectomy, potentially aiding clinical decision making.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lotan Y, Krishna V, Abuzeid WM, et al. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2024. PMID: 39383345. doi:10.1097/JU.0000000000004278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。